Exocrine-to-endocrine differentiation is detectable only prior to birth in the uninjured mouse pancreas by Kopinke, Daniel & Murtaugh, L Charles
RESEARCH ARTICLE Open Access
Exocrine-to-endocrine differentiation is detectable
only prior to birth in the uninjured mouse
pancreas
Daniel Kopinke, L Charles Murtaugh
*
Abstract
Background: Histological evidence suggests that insulin-producing beta (b)-cells arise in utero from duct-like
structures of the fetal exocrine pancreas, and genetic lineage tracing studies indicate that they are maintained in
the adult by self-renewal. These studies have not addressed the origin of the new b-cells that arise in large
numbers shortly after birth, and contradictory lineage tracing results have been published regarding the
differentiation potential of duct cells in this period. We established an independent approach to address this
question directly.
Results: We generated mice in which duct and acinar cells, comprising the exocrine pancreas, can be genetically
marked by virtue of their expressing the mucin gene Muc1. Using these mice, we performed time-specific lineage
tracing to determine if these cells undergo endocrine transdifferentiation in vivo. We find that Muc1
+ cells do give
rise to b-cells and other islet cells in utero, providing formal proof that mature islets arise from embryonic duct
structures. From birth onwards, Muc1 lineage-labeled cells are confined to the exocrine compartment, with no
detectable contribution to islet cells.
Conclusions: These results argue against a significant contribution by exocrine transdifferentiation to the normal
postnatal expansion and maintenance of b-cell mass. Exocrine transdifferentiation has been proposed to occur
during injury and regeneration, and our experimental model is suited to test this hypothesis in vivo.
Background
The origin of pancreatic islet cells has been the subject
of study and controversy since before the discovery of
insulin [1-3]. Histological and ultrastructural studies
suggested that islets arise from exocrine ducts during
embryogenesis, but whether such exocrine-endocrine
conversion continued after birth remained a matter of
controversy [4]. Nucleotide analogues have recently
been used to identify and trace the fate of proliferating
cells, but these studies have been interpreted both for
and against the hypothesis of new islet cell differentia-
tion, or neogenesis, in adulthood [5,6]. Similarly, cell
culture studies have provided evidence for and against
neogenesis, but extrapolating these findings in vivo
remains a challenge [2]. Nonetheless, determining
whether b-cell neogenesis occurs in vivo will inform
efforts to replenish b-cells lost in diabetes: if neogenesis
can occur in mice, it might be possible in the human
organ as well. Evidence against neogenesis would encou-
rage more aggressive efforts elsewhere, such as the deri-
vation of b-cells from human embryonic stem cells.
Genetic lineage tracing techniques have transformed
our understanding of pancreas developmental biology,
providing insights either unavailable from or contradic-
tory to prior studies of fixed tissue [2]. For example,
using the Cre-loxP system to monitor the fate of cells
expressing the acinar protein Carboxypeptidase A1
(Cpa1) has revealed that these cells comprise a self-
renewing, multipotent progenitor pool during mid-
embryogenesis [7]. At later stages, Cpa1
+ cells become
restricted to the acinar compartment, and lineage tra-
cing of adult acinar cells indicates that they do not con-
tribute to b-cells [7,8]. Other lineage tracing studies
similarly cast doubt on the neogenesis model; for exam-
ple, it is now appreciated that all islet cell types arise
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+ precursor cells [9], yet Neurog3
+ cells are
usually not detected after birth [10-12]. Similarly, a key
study of adult b-cell expansion and self-renewal suggests
that these processes reflect division of existing b-cells
rather than neogenesis [13], a conclusion reinforced by
subsequent independent findings [5,14].
Nonetheless, without a Cre line capable of marking
duct cells, these studies could not exclude a minor duc-
tal contribution to b- c e l l s .F u r t h e r m o r e ,t h e yh a v en o t
addressed the rapid expansion of b-cell mass that occurs
shortly after birth [15], which may derive in part from
neogenesis [6]. The ideal tool to address these questions
would be a mouse line in which ducts can be inducibly
marked at a specific time point, and their ability to con-
tribute to b-cells determined at later stages: a cellular
“pulse-chase” experiment [13]. Such mice could also
clarify the origin of new b-cells formed in regeneration
models, such as duct ligation and partial pancreatect-
omy, which may involve neogenesis [16,17]
Four transgenic mouse lines have recently been
described in studies aimed at addressing this issue.
Inada et al. [18] generated mice in which either Cre or
its tamoxifen (TM)-inducible derivative CreER™ is dri-
ven by the promoter of Carbonic anhydrase II (CAII), a
marker of adult duct cells. This study concluded that
ducts continue to give rise to islets after birth, and that
neogenesis is dramatically increased after duct ligation
[18]. Means et al. [19] used a knock-in approach to tar-
get a similar tamoxifen-inducible CreERT molecule to
the duct-specific cytokeratin-19 (K19)g e n e .K19
CreERT
labels many duct cells in neonatal and adult mice, as
well as a small fraction of islet cells due to “leaky”
recombinase expression in islets themselves. When
K19
CreERT was activated by TM treatment at birth, islet
labeling at one week of age was no greater than
expected from this background activity, suggesting that
new islet cells generated in the interim did not derive
from the more robustly-labeled duct population [19].
Finally, Solar et al. [20] generated a BAC transgenic in
which TM-dependent CreERT2 is targeted to the first
exon of Hnf1b, a transcription factor expressed selec-
tively in embryonic and adult duct cells. This study
indicated that Hnf1b
+ duct cells give rise to b-cells
prior to birth but not thereafter, even in the context of
injury models such as duct ligation [20]. The apparent
contradiction between these studies, in particular those
using CAII- and Hnf1b-driven Cre transgenes, suggests
that additional markers should be sought out and
exploited for their capacity to label duct cells, thereby
providing independent evidence for or against postnatal
neogenesis [21].
The gene mucin1, transmembrane (Muc1) is expressed
throughout the ductal network in both the embryonic
and adult pancreas, and excluded from islets [22,23].
We have generated mice in which the Muc1 gene is
tagged with an IRES-CreERT2 cassette, permitting the
inducible labeling of Muc1
+ cells. We find that this line
also marks embryonic and postnatal acinar cells, reflect-
ing endogenous Muc1 expression, but is completely
excluded from islets in short-term “pulse” experiments.
In the embryo, Muc1
+ cells give rise to endocrine cells
as well as their Neurog3
+precursors, formally confirming
that islets originate from fetal ducts. Following birth,
however, we find that the Muc1
+ lineage completely
fails to contribute to new islet a-o rb-cells, indicating
that both the expansion and homeostasis of these cell
types occurs independent of contribution from exocrine
ducts or acini. These results argue against a major role
for neogenesis in the normal postnatal pancreas, and set
the groundwork for studies of potential neogenesis dur-
ing regeneration.
Results
Targeting CreERT2 to the Muc1 locus
To determine if the Muc1 locus could be exploited to
mark ducts, we evaluated its expression in the embryo-
nic and adult pancreas. We find that Muc1 is widely
expressed at E11.5, when most pancreatic cells are still
undifferentiated progenitors (Figure 1A-C). As embryo-
genesis proceeds, Muc1 expression persists in the
branching epithelial network (Figure 1D-F), and it is
expressed by all ductal cells of the mature organ (Figure
1G-I). Another duct marker, cytokeratin-19 (CK19), is
undetectable prior to E17.5 (Figure 2). Interestingly,
Muc1 expression appears to decrease as duct caliber
increases, opposite to CK19 (Figure 2G-I). Nonetheless,
we have not observed, at any stage, a Muc1-negative cell
incorporated within a duct structure.
Embryonic islet precursors express the transcription
factor Neurogenin3 (Neurog3), and are considered to
arise from primitive duct-like cells [4,9-11]. We find
that Neurog3 expression localizes within or in close
proximity to Muc1
+ cells at E15.5, consistent with a
ductal origin for islet cells (Figure 3A). While Neurog3
expression is not detectable in adults, Muc1 remains
expressed throughout the ductal network of the pan-
creas, including large ducts as well as fine terminal
branches within acini (Figure 3B). Importantly, Muc1
expression is excluded from islet cells during embryo-
g e n e s i sa sw e l la si nt h em a t u r eo r g a n( F i g s .1 ,3 C ) .
Altogether, Muc1 appears to satisfy our requirements
for a Cre driver line to study islet neogenesis: it is
expressed in all duct cells, embryonic and adult, and
excluded from differentiated islets.
As detailed in the Methods, we generated a Muc1
IRES-
CreERT2 allele (henceforth, Muc1
IC2)b yg e n et a r g e t i n g ,
introducing an IRES-CreERT2 c a s s e t t ea f t e rt h ee n d o -
genous stop codon of the Muc1 locus (Figure 3D-E).
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recombinase that provides temporal control of Cre
activity [24], which should allow us to investigate the
differentiation potential of embryonic and postnatal duct
cells. Muc1
IC2 heterozygous and homozygous mice are
viable and fertile (data not shown).
Muc1
IC2 marks exocrine cells in the adult pancreas
To determine whether Muc1
IC2 marks ducts, we per-
formed short-term labeling experiments with the Cre-
dependent EYFP reporter strain, Rosa26
EYFP [25]. We
induced recombination by treating adult (6-8 week-old,
n=3 )Muc1
IC2/+;Rosa26EYFP
/+ mice with a single dose
of 10 mg tamoxifen. After a two-day “chase” period, we
found the EYFP lineage label not only in cytokeratin-
19
+ duct cells (~6%), as expected, but also within amy-
lase
+ acinar cells (Figure 4A-E, ~12%), indicating that
this Cre line is active in both duct and acinar cells.
(Note that in this and other experiments, we find that
Rosa26
EYFP appears to drive stronger EYFP expression
in acinar cells than ducts.) An identical labeling distribu-
tion was observed using a different reporter strain,
Rosa26
LacZ [26] (data not shown). In these and other
experiments, all Muc1
IC2-labeled cells were found to be
E-cadherin
+ (data not shown), indicating that they
represent pancreatic parenchymal cells rather than con-
nective tissue or vasculature.
Having observed the lineage label in acinar cells, we
wanted to confirm that these cells actually express
Muc1. After enzymatic dissociation and immunostaining
of isolated acini, we detect Muc1 not only within small
acini, comprised entirely of amylase
+ cells, but also in
single amylase
+ cells (Figure 5A-F). Confocal imaging of
wholemount stained pancreata confirmed that Muc1
protein localizes to the apical poles of acinar cells, and
is readily detected within individual acini that lack
Figure 1 Muc1 expression during pancreas development. Double-immunofluorescence was performed to detect Muc1 (green) and the pan-
epithelial marker E-cadherin (red) in sections of embryonic and neonatal pancreata. Muc1 is already strongly expressed in the E11.5 pancreatic
epithelium (A-C), when most cells are still undifferentiated progenitors. From E15.5 (D-F) through birth (G-I) Muc1 expression remains strong and
becomes restricted to cells lining ductal (du) and acinar (ac) lumens. Islet cells (is) do not express Muc1 at any stage. Scale bar: 100 μm.
Abbreviations: ac, acinus; du, duct; is, islet.
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Page 3 of 16Figure 2 Comparison of Muc1 and CK19 staining. Double-immunofluorescence was performed to detect Muc1 (green) and cytokeratin-19
(CK19, red) in sections of embryonic and adult pancreata. (A-C) At E15.5, CK19 is undetectable while Muc1 is strongly expressed throughout the
pancreatic ductal epithelium. (D-F) CK19 expression is first detected in larger ducts at E17.5, but remains weak or undetectable in smaller ones,
while ducts of all sizes express Muc1. (G-I) In the adult pancreas, Muc1 protein is detected in all ducts, albeit at slightly lower levels in
intralobular (closed arrowhead) than intercalated ducts (open arrowhead). (Insert in G demonstrates that Muc1 is expressed by all duct cells.)
CK19 exhibits the opposite staining pattern, highest in intralobular and lowest in intercalated ducts. Scale bars: 100 μm.
Figure 3 Muc1 expression and gene targeting. (A) At E15.5, Muc1 (green) is expressed by the ductal core, in which Neurog3
+ islet precursors
(white, indicated by yellow arrowheads) appear to reside, as well as within the terminal elements of the epithelial network, adjacent to amylase-
expressing acini (red). (B) While Muc1 remains strongly expressed throughout the adult ductal tree, Neurog3 is not detectable. (C) Muc1 (green)
is not detected within or adjacent to adult islet b-cells (insulin, red) or a-cells (glucagon, white). Inset depicts Muc1 staining alone (white), with
islet boundaries indicated by dashed line. (D) Structure of Muc1 locus, targeting vector and targeted allele. The targeting vector was designed to
introduce an IRES-CreERT2 cassette downstream of the Muc1 stop codon, along with a FRT-flanked neo
R construct for positive G418 selection and
a tk gene at the end of each homology arm for negative FIAU selection in ES cells. Dotted lines indicate the boundaries of the 5’ and 3’
homology arms used for targeting, and the probe used for Southern blotting (outside the 5’ homology arm) is indicated in red. Correct
targeting introduces a new XbaI site, shifting the predicted restriction fragments detected by this probe. (E) Southern blotting of Muc1
IC2neo ES
cells and mice. Xba1 digests of genomic DNA prepared from ES cells (parental R1 cells or targeted clone DK5.25), as well as from putative
Muc1
IC2neo/+ F1 offspring of DK5.25 chimeras (genotyped by PCR), were hybridized with the probe indicated in panel A. Targeted ES cells and
mice display both wildtype (11 kb) and IC2neo (8.5 kb) XbaI fragments. Scale bars: 100 μm. Abbreviations: ac, acinus; du, duct; is, islet.
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IRES-CreERT2 is active in adult exocrine cells. (A-C) Recombination was induced in adult (P60) Muc1
IC2/+;Rosa26
EYFP/+ mice by
administration of 10 mg tamoxifen, and mice were analyzed 2 days later by immunofluorescence for EYFP (green), amylase (B, red) and
cytokeratin-19 (C, red), together with DAPI (blue) to mark nuclei. After a short term chase, Muc1
IC2 marks cells of the ductal network (closed
arrowheads) as well as acinar cells (open arrowheads), suggesting that Muc1 is expressed in both duct and acinar cells. (D-E) Ductal Rosa26
EYFP
labeling by Muc1
IC2, shown in fields devoid of labeled acinar cells (D, magnified from panel C; E, independent field). As Rosa26
EYFP expression is
lower in duct cells than acini, we have increased the green signal in these panels to make ductal staining more obvious. (F) 8-month old TM-
untreated control mouse, stained for EYFP (green), amylase (red) and cytokeratin-19 (white). Less than 0.1% of duct and acinar cells are labeled
in the absence of TM. Scale bars: 100 μm. Abbreviations: ac, acinus; du, duct; is, islet.
Figure 5 Muc1 localization within acinar structures. (A-F) Immunofluorescence of dissociated wildtype acini for Muc1 (green), amylase (red)
and DAPI (blue). Muc1 is detected within small clusters of amylase
+ acinar cells as well as in single amylase
+ cells, suggesting that these cells, as
well as ducts, express the Muc1 gene. (G-I) Confocal z-projection (0.75 μm) of adult wildtype pancreas, wholemount stained for Muc1 (green),
E-cadherin (red) and DAPI (blue). Outline in I indicates a single acinar unit, with a shared central lumen. Membrane-bound Muc1 protein localizes
to this central lumen (open arrowhead), as well as extending between two individual acinar cells (closed arrowhead). Note that there appears to
be no centroacinar cell in this cluster, the lumen of which is entirely defined by the apical surfaces of adjacent acinar cells, and coated by Muc1
protein. Scale bars: 10 μm.
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Page 5 of 16centroacinar cells [27] (Figure 5G-I). Since this antibody
recognizes the intracellular domain of the Muc1 protein
[28], the observed staining is unlikely to reflect shed or
contaminating Muc1 from duct or centroacinar cells. In
situ hybridization studies have similarly revealed MUC1
expression in both acinar and duct cells of the human
pancreas [29], and we conclude that the acinar labeling
observed with Muc1
IC2 reflects endogenous Muc1
expression.
We also determined the relative distribution of
Muc1
IC2-labeled cells between small (intercalated), med-
ium (intralobular) and large (interlobular) ducts (Figure
6A-C). We found that Muc1
IC2-labeled cells were pre-
sent in all three duct types, with slightly lower labeling
within interlobular ducts than those of smaller caliber
(Figure 6D). This labeling distribution is consistent with
the distribution of Muc1 protein itself, described above
(Figure 2), and suggests that Muc1
IC2-driven recombina-
tion can occur in any Muc1-expressing cell.
Examining TM-untreated 4-8 month Muc1
IC2/+;
Rosa26EYFP
/+ and Muc1
IC2/+;Rosa26LacZ
/+ mice (n = 3)
revealed a background recombination rate of less than
0.1% (Figure 4F and data not shown), confirming that
this line exhibits stringent tamoxifen dependence.
Furthermore, we never observed lineage-labeled endo-
crine cells in our short-term experiments. Muc1
IC2
labeling is thus TM-dependent, as expected, and extends
throughout the exocrine pancreas (acini and ducts).
Although TM-induced Muc1
IC2 labeling is relatively
sparse (5-15% of exocrine cells, in this experiment), its
distribution closely matches that of Muc1 itself, and
appears to represent a random sampling of the exocrine
pancreas. As Muc1
IC2 does not directly label islet cells,
it can be used to detect potential exocrine-derived
neogenesis.
Islet cells arise from embryonic Muc1
+ cells
To determine whether Muc1
+ cells contribute to islet
neogenesis in utero, we administered tamoxifen to preg-
nant females carrying Muc1
IC2/+; Rosa26EYFP
/+
embryos. These experiments yielded a very low overall
labeling rate (≤1% of any cell type, data not shown),
possibly due to reduced amounts of TM entering fetal
circulation. To increase the cellular Cre concentration,
therefore, we used homozygous Muc1
IC2/IC2;
Rosa26EYFP
/+ embryos for all in utero labeling experi-
ments. Muc1
IC2/IC2;Rosa26EYFP
/+ embryos were labeled
w i t has i n g l em a t e r n a ld o s eo fT M( 5 - 1 0m g )a td i f f e r -
ent embryonic stages: E11.5, E13.5 or E15.5. All embryos
were analyzed at E17.5 (n = 3 for each tamoxifen treat-
ment group). As expected, Muc1
IC2 labels fetal ducts at
all these timepoints (Figure 7A and data not shown),
albeit at low frequencies (2-6%, Figure 7B). Consistent
with its labeling pattern in the adult pancreas, Muc1
IC2
marks a similar proportion of fetal acinar cells as well
(Figure 3B and data not shown). Furthermore, we
observe EYFP lineage-labeling of insulin
+ b-cells and
glucagon
+ a-cells in all of these pancreata (Figure 7B-
D), indicating an origin within the Muc1
+ exocrine com-
partment. Our experimental design therefore identifies
potential neogenesis even from a sparsely-labeled popu-
lation. As b-cell numbers increase exponentially between
E11.5 and E17.5 [30], ~100-fold total, most of the b-cells
analyzed in this experiment would have been born since
tamoxifen was administered. That we find comparable
Muc1
IC2 lineage labeling in b-cells and exocrine cells
(Figure 7B) suggests that most of the new b-cells arose
via exocrine-derived neogenesis.
To further confirm that Muc1
IC2 is not active in fetal
islets themselves, we performed short-term (12-14 hr)
pulse-chase labeling of embryos at E13.75 or E14.75. We
could easily detect the lineage label in the embryonic
ductal system as well as in Neuog3
+ cells (Figure 8A-B),
but failed to detect any labeled hormone-producing cells
(Figure 8C-D). The short-term labeling of Neurog3
+
cells agrees with the co-expression of Neurog3 and
Muc1 in embryonic ducts (Figure 3A), and the lack of
short-term islet labeling confirms that the later appear-
ance of labeled endocrine cells reflects differentiation
from exocrine tissue.
Finally, to determine whether fetal Muc1
+ cells con-
tribute to adult islets, we administered 5 mg TM to
pregnant females at E14.5 and analyzed labeling at
weaning age (P21). We found labeling of both b-cells
(2.2 +/- 0.4%) and a-cells (2.1% +/- 0.2%), present in
mature islet structures (Figure 9). As expected, lineage
label also persists in adult duct cells, and appears to be
distributed equally among various classes of duct struc-
tures (Figure 6D).
Altogether, these results strongly suggest that (a)
embryonic Muc1
+ duct cells give rise to all segments of
the adult ductal network, (b) Muc1 is not expressed by
endocrine cells and (c) mature islet cells arise from Neu-
rog3
+ precursors within the embryonic Muc1
+ ductal
network. These results represent direct evidence that
endocrine cells arise from embryonic ducts, but they
leave open the possibility that embryonic Muc1
IC2 label-
ing actually marks a ductal stem cell-like population,
which continues to give rise to new islet cells after
birth. We therefore turned our attention to the differen-
tiation potential of postnatal Muc1
+ cells.
Muc1
+ exocrine cells do not undergo endocrine
differentiation after birth
We performed three experiments to determine whether
the Muc1
+ exocrine compartment contributes to islet
cells after birth. In experiment 1, we administered 10
mg tamoxifen to young adult (~P60) Muc1
IC2/+;
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/+ mice, and assayed the potential contribu-
tion of labeled cells to either exocrine or endocrine cells
a f t e r7 ,6 0o r1 2 0d a y s( F i g u r e1 0 A - Ca n dd a t an o t
shown). We observed an overall labeling efficiency (i.e.
proportion of EYFP
+ cells per field, without reference to
cell type-specific markers) of ~24% in these experi-
ments, which included ~30% labeling of acinar and
~10% labeling of duct cells (Table 1). As our short-term
labeling experiments never revealed detectable lineage
marking of islet cells (D.K., unpublished observations),
we focused our quantitative analyses on the 60 d and
120 d chase periods. We counted randomly-chosen
fields of b-cells and a-cells, scoring separately for num-
ber of insulin
+ or glucagon
+ cells, number of EYFP
+
cells, and number of double-positive (hormone
+/EYFP
+)
cells. In fact, after scoring several thousand cells positive
for each marker (Table 2), we never observed a single b-
cell or a-cell positive for EYFP, suggesting that new islet
cells do not arise in significant numbers from adult
Muc1
+ exocrine cells.
To determine if Muc1
+ cells contribute to the rapid
expansion of islet cell numbers after birth [15], we
Figure 6 Muc1
IC2 labels cells throughout the ductal network. (A-C) Representative immunofluorescence images documenting the presence
of Muc1
IC2-labeled cells (green) within small/intercalated, medium/intralobular and large/interlobular ducts, co-stained for cytokeratin-19 (red).
Interlobular were distinguished from intralobular ducts by the presence of connective tissue separating them from acinar parenchyma. Scale bar:
50 μm. (D) Muc1
IC2 lineage-labeling indices of different duct populations, within various pulse-chase experiments. In each experiment, we
observe roughly equal labeling of intercalated (blue circle), intralobular (red triangle) and interlobular (green X) ducts, with the exception of
decreased intercalated duct labeling after tamoxifen treatment of adults (p < 0.01 by TukeyHSD).
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Page 7 of 16performed experiment 2, in which we induced recombi-
nation in Muc1
IC2/+; Rosa26
LacZ/+ neonates by adminis-
tration of tamoxifen to nursing mothers (consecutive
10 mg doses on P0 and P1). We sacrificed mice 21 or
120 days after treatment (i.e. as weanlings or mature
adults), and performed immunofluorescence to detect
LacZ lineage marker within the exocrine and endocrine
compartments (Figure 10D-F and data not shown). We
found an overall labeling efficiency of ~10% in these
experiments, including ~15% of acinar cells and ~4% of
duct cells (Table 1). As in experiment 1, however, despite
scoring several thousand cells for each marker, we did
not observe a single LacZ
+ b-cell or a-cell (Table 2).
Previous studies indicate that acinar cells do not con-
tribute to islets after birth [7,8,31], and experiment 2
suggests that neonatal duct cells are also excluded from
the islet lineage. This interpretation hinges on relatively
infrequent ductal labeling, which could have hidden a
low level of duct-derived neogenesis. To increase the
duct labeling frequency, we performed experiment 3, in
which we directly injected newborn Muc1
IC2/+;
Rosa26EYFP
/+ pups with tamoxifen (2 mg per pup,
delivered subcutaneously). Upon sacrifice, 21 days after
TM administration, we found increased overall labeling
compared to mice that received maternal TM (~30%
EYFP
+,T a b l e1 ) .I m p o r t a n t l y ,t h ed u c tl a b e l i n g
Figure 7 Muc1
+ cells give rise to endocrine cells during embryogenesis. (A) A single dose of 5 mg tamoxifen was given to pregnant mice
at E11.5, and pancreata of Muc1
IC2/IC2; Rosa26
EYFP/+ offspring were analyzed at E17.5 by immunofluorescence for EYFP (green), DBA lectin (red)
and DAPI (blue). Arrowheads indicate DBA
+ cells co-expressing EYFP. (B) Quantification of observed co-labeling at E17.5, following tamoxifen
administration at indicated time points. Scatter plot depicts the percentages of DBA
+ (orange), amylase
+ (green), insulin
+ (red) and glucagon
+
(blue) cells co-expressing EYFP. Each point represents an independent embryo, and means are indicated by dotted lines. (C-D) Pancreata of
Muc1
IC2/IC2; Rosa26
EYFP/+ embryos, administered TM at E11.5 as in (A), stained at E17.5 for EYFP (green), insulin or glucagon (red) and DAPI (blue).
Inserts: confocal z-projection (1.36 μm) of the boxed areas, to confirm localization of EYFP to hormone-producing cells. Scale bars: 25 μm.
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among interlobular, intralobular and intercalated ducts
(Figure 6D). Nonetheless, we did not observe any
labeled b-cells or a-cells, despite scoring several thou-
sand cells positive for each marker (Table 2).
These analyses suggest an upper limit to the contribu-
tion of neogenesis to postnatal islet growth. b-cell mass
has been reported to expand between 4- and 10-fold in
the first 2-4 weeks after birth [32-34]. If we assume a
five-fold expansion between P0 and P21, we can infer
that ~80% of the b-cells scored in experiment 3 were
“new” since P0 (3600 of the ~4500 b-cells counted,
Table 2). If all of these had been derived from Muc1
IC2-
labeled duct cells, given a duct labeling index of ~10%
(Table 1), we would have expected to observe roughly
360 labeled b-cells. As we observed zero, we conclude
that ≤1% of all b-cells generated after birth could have
arisen from labeled ducts (1% neogenesis would have
resulted in ~4 labeled b-cells, which is probably near
the limit of reliable detection). Altogether, experiments
1-3 fail to reveal duct-to-islet transdifferentiation after
birth.
Discussion
At birth, the mammalian b-cell changes from a meta-
bolic passenger to the driver of glucose homeostasis.
Based on our results and those of Solar et al. [20], we
propose that the mechanisms controlling b-cell mass
also change at birth, from a fetal period of new differen-
tiation, or neogenesis, to a mature state of self-renewal
(Figure 11). To detect this transition, we performed a
direct comparison of duct and acinar cell lineages before
and after birth. We provide formal proof – confirming
prior studies of histology and gene expression – that
islets arise from embryonic Muc1
+ ducts. From birth
onwards, however, we find no evidence for a ductal
Figure 8 Neurog3
+ cells arise from Muc1
+ ductal cells during embryogenesis. To detect the short-term differentiation potential of Muc1
+
cells, Muc1
IC2/IC2; Rosa26EYFP
/+ embryos were labeled by TM administration to pregnant dams at E13.75 (A, C) or E14.75 (B, D), and harvested
~12 hours later for immunofluorescence analysis (n = 2 for each timepoint). (A-B) Short-term labeling of Muc1
+ cells (green) reveals their
presence within the E-cadherin
+ ductal network (blue, open arrowheads), as well as their contribution to Neurog3
+ cells (red, closed
arrowheads). (C-D) Similar analysis of islet hormone expression indicates that Muc1
IC2 labeling (green, open arrowheads) is excluded from insulin
+
(red) and glucagon
+ cells (white), confirming that these cells derive from Muc1
+ progenitors but do not themselves express Muc1. Scale bars: 50
μm in A-B and 100 μm in C-D.
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Page 9 of 16Figure 9 Postnatal islet cells derive from embryonic Muc1
+ progenitors. Muc1
IC2/IC2; Rosa26
EYFP/+ mice received tamoxifen in utero (5 mg to
pregnant dam at E14.5), and were analyzed at P21 by immunofluorescence for EYFP lineage label (green), insulin (A-C, red) and glucagon (D-F,
red). After inducing the Muc1 lineage at E14.5 and chasing offspring until P21, EYFP labeling (white arrowheads) is detected among both insulin
+ b-cells (2.2 +/- 0.4%) and glucagon
+ a-cells (2.1 +/- 0.2%). Scale bar: 50 μm.
Figure 10 The Muc1 lineage does not contribute to islets after birth.( A - C )Experiment 1: adult Muc1
IC2/+; Rosa26
EYFP/+ mice (P60) were
treated with a single dose of 10 mg tamoxifen, and analyzed after a 120 d chase period (i.e. to six months of age). Immunofluorescence was
performed for EYFP lineage label (green), cytokeratin-19 (A, red), insulin (B-C, red) and glucagon (B, white). Lineage label remains restricted to the
exocrine compartment (arrowheads indicate labeled duct cells). (D-F) Experiment 2: Muc1
IC2/+; Rosa26
LacZ/+ neonates received TM via maternal
gavage (sequential 10 mg doses at P0 and P1), and were analyzed after 120 d by immunofluorescence as per A-C (using LacZ, in green, as
lineage label). LacZ labeling is confined to duct (white arrowheads) and acinar cells, with no detectable expression in islet cells. Scale bars: A-B
and D-E, 100 μm; C and F, 25 μm. Abbreviations: du, duct cells; ac, acini.
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Page 10 of 16origin of new b-cells, and we propose that postnatal b-
cell expansion and homeostasis normally occur without
contribution from ducts or acini.
We had intended, in creating the Muc1
IC2 allele, to
specifically address the differentiation potential of duct
cells. Instead, we find that Muc1
IC2 labels both acinar
and duct cells, at all stages examined, and that Muc1
protein is readily detected within acinar cells. Nonethe-
less, we can treat the labeling of postnatal acinar cells as
“background,” as acinar-to-islet transdifferentiation does
not occur after birth [7,8,31]. Cells expressing the acinar
enzyme Cpa1 do behave as multipotent “tip cell” progeni-
tors prior to E13.5, but are thereafter restricted to the
acinar lineage [7]. As Muc1
+ cells still contribute to islets
at E13.5 and E15.5 (Figs. 7, 9), we propose that islet dif-
ferentiation competence normally shifts from Muc1
+/
Cpa1
+ tips to Muc1
+/Cpa1-negative “trunks” after E13.5,
before being lost entirely at birth (Figure 11).
Another recently developed mouse line, K19
CreERT,i n
which CreERT is targeted to the cytokeratin-19 locus,
drives TM-dependent recombination in inter- and intra-
lobular ducts [19]. Unlike Muc1
IC2, K19
CreERT does not
label distal intercalated ducts, and is active in a small
fraction of islet cells. Nonetheless, preliminary experi-
ments reported using K19
CreERT provide independent
evidence supporting our model: TM treatment at birth
Table 1 Muc1
IC2 lineage contribution to exocrine cells
Lineage
+ (EYFP or LacZ)
Experiment Genotype Pulse protocol Chase period Sample # % of DAPI
+ % of AMY
+ % of CK19
+
1 Muc1
IC2/+; Rosa26
EYFP/+ adult (P60)
10 mg TM
gavage
7d 1 23.6 29.3 7.5
2 22 27.3 6.2
3 24.3 32.2 5.4
mean 23.3 ± 0.7 29.6 ± 1.4 6.4 ± 0.6
120 d 1 30 42.4 8.5
2 12.6 15 11.7
3 20.8 26.4 10.1
4 33 43.6 14.5
5 23.6 30.6 13.3
mean 24.0 ± 3.6 31.6 ± 5.3 11.6 ± 1.1
overall mean 23.7 ± 2.2 30.8 ± 3.2 9.6 ± 1.2
2 Muc1
IC2/+; Rosa26
LacZ/+ pups
(P0/P1)
10 mg TM
maternal gavage
21 d 1 16.6 22.9 9.9
2 11.7 15.5 3.6
3 3.3 4.1 1.8
4 6.2 7.4 1.9
5 5.1 5.9 1.5
mean 8.6 ± 2.4 11.2 ± 3.5 3.7 ± 1.6
120 d 1 14.1 21.9 5.5
2 21.4 30.9 6.2
mean 17.7 ± 3.7 26.4 ± 4.5 5.8 ± 0.4
overall mean 10.6 ± 2.5 15.5 ± 3.8 4.3 ± 1.2
3 Muc1
IC2/+; Rosa26
EYFP/+ pups (P0)
2m gT M
SQ
21 d 1 21.7 ND 8.9
2 22.8 7.8
3 51.1 13.5
mean 31.9 ± 9.6 10.1 ± 1.7
Three “pulse-chase” lineage-labeling experiments were performed, as described in the text, in which tamoxifen was administered (by oral gavage to adults, or
subcutaneous injection to neonates) and mice sacrificed after chase periods of 7-120 days. For each sample, we counted total cells per field (DAPI), acinar cells
(amylase
+) and duct cells (cytokeratin-19
+), as well as the number of cells double-positive for these markers and for the lineage tracer. From these counts, we
derived the labeling efficiency (expressed as a percentage) of total cells (DAPI), acinar (AMY) and duct (CK19) cells. Shown are summary data for every mouse
analyzed, as well as mean values +/- standard error. ND, not determined.
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Page 11 of 16Table 2 Quantification of potential Muc1 contribution to endocrine cells
number of cells scored
Experiment Genotype Pulse protocol Chase period Sample # lineage
+ INS
+ GLU
+
1 Muc1
IC2/+; Rosa26
EYFP/+ adult (P60)
10 mg TM
gavage
60 d 1 2950 2054 ND
2 959 1398
total 3909 3452
120 d 1 1588 624 209
2 1416 498 144
3 1266 1069 374
4 2089 2004 703
5 1199 1488 409
6 1079 904 369
total 8637 6587 2208
2 Muc1
IC2/+; Rosa26
LacZ/+ pups
(P0/P1)
10 mg TM
maternal gavage
21 d 1 221 590 276
2 483 745 235
3 266 1045 436
total 970 2380 947
120 d 1 2072 2152 626
2 2637 1847 315
total 4709 3999 941
3 Muc1
IC2/+; Rosa26
EYFP/+ pups (P0)
2m gT M
SQ
21 d 1 1566 2017 999
2 1264 950 488
3 3508 1570 564
Total 6338 4537 2051
As described in the text, mice subjected to “pulse-chase” labeling with Muc1
IC2 were analyzed for potential contribution of lineage-marked cells to insulin
+ b-cells
or glucagon
+ a-cells (exocrine labeling results in Table 1). Indicated are the total number of cells scored as positive for lineage label (EYFP or LacZ), as well as the
total number of insulin
+ and glucagon
+ cells scored in the same fields. In no case did we observe a lineage label-positive endocrine cell. ND, not determined.
Figure 11 Dynamic differentiation potential within theexocrine pancreas. Multipotent pancreatic progenitors (E11.5-E13.5) express the
digestive enzyme Cpa1, which is later restricted to acinar cells (E14.5-adult), together with Muc1 and Hnf1b [20]. While Cpa1
+ cells cease
contribution to islets from approximately E13.5 [7], Muc1
+/Hnf1b
+ cells continue to give rise to Neurog3
+ endocrine precursors (pink nuclei) and
islets (blue and green) through at least E15.5. From around birth, Muc1
+ and Hnf1b
+ cells no longer contribute to the endocrine lineage, and
mature islets are maintained by self-replication of those pre-existing. However, it remains a formal possibility that a subpopulation exists within
the ductal network (dark blue cytoplasm), expressing neither Muc1 nor Hnf1b, from which b-cells continue to arise after birth.
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Page 12 of 16results in ≥10% labeling of ducts after one week, but
<1% labeling of islets, equivalent to the direct activity of
this line in islet cells themselves [19].
While this manuscript was in preparation, Solar and
colleagues [20] published a study using another exocrine
CreERT2 line, driven by the Hnf1b locus. Unlike
Muc1
IC2, this driver is not active in acini, and labels a
higher fraction of duct cells postnatally (approximately
20% at birth and 40% in adults, compared to 10% label-
ing at either timepoint with Muc1
IC2). As with Muc1
IC2,
lineage-tracing of Hnf1b
+ cells revealed duct-to-islet dif-
ferentiation prior to birth, but none thereafter. Further
experiments by these investigators indicate that such
differentiation does not occur in the context of injury
and regeneration [20], as previously believed [16]. Our
data provide further evidence against postnatal duct-to-
islet differentiation in the healthy pancreas, although it
remains to be determined if injury can induce neogen-
esis from Muc1
IC2-expressing population.
The Hnf1b-CreERT2 and Muc1
IC2 lineage tracing
results contradict those obtained with a Cre transgene
driven by the Carbonic anhydrase II promoter (CAII-
Cre) [18]. Using Rosa26
LacZ reporter mice to detect
recombination [26], these authors report that CAII-Cre
drives duct-restricted recombination beginning at E18.5,
but labels roughly 15% of b-cells at four weeks of age.
We cannot offer an obvious explanation for this discre-
pancy; given the number of b-cells that we counted, we
should have detected such a robust contribution from
Muc1
IC2-labeled duct cells. One possibility is that CAII-
Cre-catalyzed recombination actually begins prior to
birth, when Neurog3
+ cells are still present [10,11], but
that LacZ expression cannot be detected until one or
more days after birth. In fact, half of the newborn pan-
creata examined in this study already exhibited at least
some labeled b-cells (in one pup, as many as 70% of
islets contained labeled b-cells), indicating prenatal
recombination [18]. These authors have also generated a
CAII-CreERT transgene, which could be used to follow
postnatal labeling specifically, although their experi-
ments with these mice revealed surprisingly high levels
of tamoxifen and Cre-independent LacZ expression in
adult islets [18].
Alternatively, a subpopulation of duct cells with the
capacity for islet differentiation might escape labeling by
Muc1
IC2, K19
CreERT and Hnf1b-CreERT2, but not by CAII-
Cre (Figure 11). Indeed, as neither our Cre driver nor
those described by others labels a majority of postnatal
duct cells [19,20], the possibility of a substantial unmarked
subpopulation is impossible to exclude formally. As three
independent and distinct Cre transgenes have yielded
identical conclusions, however, the burden of evidence
would appear to weigh against postnatal islet neogenesis.
With respect to Muc1
IC2 in particular, we note that
although its recombination efficiency in utero is even
lower than after birth, our experimental approach still
identifies islet cells arising from the sparsely labeled
embryonic exocrine compartment. Furthermore, we
have never observed a Muc1-negative duct cell (Figs. 1,
2, 3, and data not shown), nor is there evidence for ana-
tomical exclusion of Muc1
IC2-labeled cells within the
ductal network (Figure 6). We also do not observe any
obvious change in Muc1 expression or distribution
between embryonic stages, when Muc1
IC2 does label
endocrine cells, and postnatal stages, when it does not.
An obvious transition that does occur perinatally is the
extinction of Neurog3 expression, which itself weighs
against the persistence of duct-to-islet differentiation
after birth [10,11].
From a physiological perspective, it might make
sense that expansion of b-cells after birth involves a
mechanism independent of neogenesis, as postnatal b-
cells must contend with metabolic demands from
which embryonic progenitor cells are buffered. In fact,
numerous knockout mouse studies indicate the exis-
tence of postnatal-specific mechanisms to control
b-cell mass [32,35-39]. Furthermore, recent studies
s u g g e s tt h a te x p a n s i o no fb-cell mass in adults, in
response to b-cell damage or increased insulin
demand, occurs via prolifera t i o nr a t h e rt h a nn e o g e n -
esis [13,37,40]. Potential exceptions to this rule have
been described, including partial pancreatectomy and
duct ligation, in which development of new b-cells is
accompanied by the re-appearance of Neurog3-expres-
sing cells within the ductal epithelium [16,17]. Studies
using Hnf1b-CreERT2 to mark pre-existing duct cells
in such models did not detect contribution to new
b-cells, however [20]. The Muc1
IC2 line is well suited
for similar experiments and, as a tool to mark cells
throughout the exocrine pancreas, it should comple-
ment and extend results obtained by others.
Conclusions
Our results constitute formal evidence that insulin-pro-
ducing b-cells, and other endocrine cells of the mature
pancreatic islet, derive from ductal cells of the embryo-
nic organ. Furthermore, the ability to trace the lineage
of cells expressing Muc1 at different timepoints allows
us to compare their differentiation potential before and
after birth. We find that Muc1-expressing cells lose the
capacity for islet differentiation postnatally, prior to the
major increase in b-cell numbers that occurs in juvenile
mice. These data add to an emerging model for control
of b-cell mass, driven by developmentally-programmed
neogenesis in the womb and physiologically-regulated
proliferation after birth.
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Targeting CreERT2 to the Muc1 locus
We followed the procedure of Wu et al. [41] to generate
a Muc1
IRES-CreERT2-neo (Muc1
IC2neo) targeting vector. In
brief, we recombineered a 9.2 kb fragment of the mouse
Muc1 gene from a 129Sv BAC library (clone bMQ-
356N19, from the Sanger Institute) into a conventional
plasmid, introduced an IRES-CreERT2-FRT-neo
R-FRT
cassette after the endogenous Muc1 stop codon, and
flanked the homology arms with thymidine kinase (tk)
cassettes (Figure 3D). The targeting vector was then
electroporated into R1 ES cells [42], generously provided
by Mario Capecchi, which were selected with G418 and
FIAU [43]. 52/96 of the surviving clones exhibited
homologous recombination upon Southern blotting with
a probe located outside the 5’ homology arm. Proper
recombination was confirmed for 8/8 of these upon
further Southern analyses, and one of these clones,
DK5.25 (Figure 3E), was used to generate chimeras
(University of Utah, Transgenic Core Facility).
Animal experiments
After initial backcrossing to C57BL/6, F1 offspring of a
DK5.25 chimera (Figure 3E) were bred to Rosa26
FLPo
deletor mice [44], obtained from the Jackson Laboratory
(Bar Harbor, ME), to delete the FRT-flanked neo
R cas-
sette. neo
R excision yielded the Muc1
IRES-CreERT2
(Muc1
IC2) allele (data not shown). Multiplex PCR geno-
typing, producing bands of 357 bp (wildtype) and 464
bp (mutant), was performed using oligos: wt forward: 5’-
AATGGCAGTAGCAGTCTCTC-3’;w tr e v e r s e :5 ’-
CACAGCTGGCATAACTAACA-3’; and mutant reverse:
5’-CCACAACTATCCAACTCACA-3’. Muc1
IC2 mice
were maintained on a CD1 outbred background. Cre
reporter mice Rosa26
EYFP [25] and Rosa26
LacZ [26] were
obtained from the Jackson Laboratory.
Tamoxifen (Sigma T-5648) was dissolved in corn oil,
and administered by oral gavage at doses of 5-10 mg to
adult mice, or 2 mg by subcutaneous injection of neo-
nates. For timed-pregnancy studies, noon on the day
after vaginal plugging was considered embryonic day 0.5
(E0.5). All animal procedures were approved by the
Institutional Animal Care and Use Committee.
Immunostaining and analysis
Tissue fixation, processing and immunostaining were
performed essentially as described [45]. Tissues were
fixed with 4% paraformaldehyde (PFA) in PBS for
1-2 hrs at 4°C, embedded in OCT and cryosectioned at
7-8 μm thickness. Primary antibodies used in this study
are listed in Table 3. Secondary antibodies were pur-
chased from Jackson Immunoresearch. To calculate
labeling efficiencies, we photographed 5-12 randomly
selected 20× fields per stained specimen, across 4-8 sec-
tions separated by 100-150 μm. The total number of
each cell type (DAPI for total cells per field, LacZ or
GFP for Muc1
IC2-labeled cells, insulin and glucagon for
endocrine cells, amylase, cytokeratin-19 and DBA lectin
for exocrine cells) was determined using the Analyze
Particles function of ImageJ (NIH). Double-positive cells
were detected by additive image overlay, in ImageJ, of
the DAPI channel with lineage
+ and marker
+ staining.
Accuracy of counts was confirmed by eye in Adobe
Photoshop for random samples. Calculations and graphs
were generated with Microsoft Excel and R http://www.
r-project.org.
Acinar isolation and staining
Acini were isolated by sequential trypsin and collagenase
P digestion of minced dorsal pancreas, as described [46],
PFA-fixed for 15 min and adhered to microscope slides
by cytospin (Thermo-Fisher). Cytospin slides were
Table 3 Primary antibodies used in this study
Antigen Species Source Catalog # Dilution
amylase sheep BioGenesis 0480-0104 1:2500
amylase rabbit Sigma A8273 1:1000
cytokeratin-19 rat Developmental Studies Hybridoma Bank TROMA-3 1:50
cytokeratin-19 rabbit Ben Stanger (University of Pennsylvania) 1:1000
C-peptide rabbit Linco 4020-01 1:2500
C-peptide goat Linco 4023-01 1:5000
E-cadherin rat Zymed/Invitrogen 13-1900 1:2000
GFP rabbit Abcam ab290 1:4000
GFP goat Rockland 600-101-215 1:2500
glucagon rabbit Zymed/Invitrogen 18-0064 1:250
glucagon guinea pig Linco 4031-01F 1:2500
LacZ rabbit Cappel/MP 55976 1:2000
Muc1 hamster NeoMarkers HM-1630-P1 1:500
Neurog3 mouse Developmental Studies Hybridoma Bank I25A1B3 1:75
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Page 14 of 16stained as per cryosections. For wholemount immuno-
fluorescence of intact tissue, small pieces of the dorsal
pancreas were excised and PFA-fixed as above, washed
with PBS, permeabilized with 1% Triton X-100 in PBS
and stained with primary and secondary antibodies
(overnight incubations, followed by extensive PBS/0.1%
Tween-20 washes).
Abbreviations
Cpa1: carboxypeptidase A1; CK19: cytokeratin-19; DAPI: 4’,6-diamidino-2-
phenylindole; DBA: Dolichos biflorus agglutinin; EYFP: enhanced yellow
fluorescent protein; FIAU: 1-(-2-deoxy-2-fluoro-1-b-D-arabinofuranosyl)-5-
iodouracil; GFP: green fluorescent protein; IRES: internal ribosome entry
sequence; PFA: paraformaldehyde; TM: tamoxifen.
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